《復牌公告》中國奧園(03883.HK)已履行復牌指引 債務重組進展良好
中國奧園(03883.HK)公布,公司已履行復牌指引,主要包括刊發所有尚未刊發的財務業績,並處理任何審核修改;證明並無與管理層誠信及/或對公司管理及經營有重大影響的人士的誠信合理監管疑問,是基於獨立調查委員會已得出結論,對事發期間亦為董事會成員的現任董事的誠信並無顧慮。
同時,公司及附屬Add Hero就於境外債務重組方案持續作出重大進展,相關文件的準備已取得良好進展,並準備向相關法院備案。預期將於不久後向相關法院開始申請程序以開展於境外債務重組的協議安排。
公司股份自2022年4月1日起暫停買賣,已申請周一(25日)恢復買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.